Phase II Single Arm study of AZD9291 to treat NSCLC patients in Asia Pacific

Trial Identifier: D5160C00017
Sponsor: AstraZeneca
NCTID:: NCT02442349
Start Date: June 2015
Primary Completion Date: March 2016
Study Completion Date: December 2022
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia Heidelberg, Australia, 3084
Australia Kogarah, Australia, 2217
Australia Kurralta Park, Australia, 5037
Australia Nedlands, Australia, 6009
Australia Woolloongabba, Australia, 4102
China Beijing, China, 100730
China Beijing, China, 100142
China Beijing, China, 100021
China Beijing, China, 100071
China Changchun, China, 130000
China Chengdu, China, 610041
China Chongqing, China, 400038
China Chongqing, China, 400042
China Fuzhou, China, 350014
China Guangzhou, China, 510100
China Haikou, China, 570311
China hangzhou, China, 310006
China Hangzhou, China, 310003
China Hangzhou, China, 310022
China Harbin, China, 150049
China jinan, China, 2501117
China Nanjing, China, 210009
China Shanghai, China, 200030
China Shanghai, China, 200032
China Shanghai, China, CN-200433
China Tianjin, China, 300060
China Wuhan, China, 430030
China Wuhan, China, 430022
China xi'an, China, 710038
China Xi'an, China, 710032
China Zhengzhou, China, 450008
South Korea Goyang-si, South Korea, 10408
South Korea Seongnam-si, South Korea, 13620
South Korea Seoul, South Korea, 05505
South Korea Seoul, South Korea, 135-710
Vietnam Ha Noi, Vietnam, 100000
Vietnam Hanoi, Vietnam, 100000
Vietnam Ho Chi Minh city, Vietnam
Vietnam Ho Chi Minh City, Vietnam, 700000